Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- July15 2003
- Volume 10
- Issue 13
Honest Doctors
Advertisement
Wall Street Journal
A recent poll of more than 2100 Americans on the financial integrity of the health care industry offers good news for physicians. According to a May 2003 /Harris Interactive Health Care Poll, America's doctors won the top marks for professional honesty and ethics when it came to financial behavior. Here are percentages of respondents who were "somewhat or very confident" in the financial ethics of these health care entities:
Articles in this issue
about 18 years ago
Less Time, More Workabout 18 years ago
One Hand Giving, Another Taking?about 18 years ago
RIP-Steven C. Campabout 18 years ago
Pay Yourself Firstabout 18 years ago
ADDING TO THE MIXabout 18 years ago
SPAMMER SLAMMEDabout 18 years ago
AUDITING THE WEALTHYabout 18 years ago
UNDER THE IRS GUNabout 18 years ago
MEDICARE RUNAROUNDabout 18 years ago
REFINANCING & TAXESAdvertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5